Skip to Main Content

Author Details

Hayley C Whitaker
University College London
1999
95
28
PMIDPaper TitleJournal TitlePublished Year
36725887Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.Oncogene2023
37550801ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression.J Pathol2023
37607794Use of artificial intelligence in the detection of primary prostate cancer in multiparametric MRI with its clinical outcomes: a protocol for a systematic review and meta-analysis.BMJ Open2023
37769532Prostate MR image quality of apparent diffusion coefficient maps versus fractional intracellular volume maps from VERDICT MRI using the PI-QUAL score and a dedicated Likert scale for artefacts.Eur J Radiol2023
35414034Diagnostic potential of radiological apical tumor involvement.J Robot Surg2023
36855895Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging.BJU Int2023
36810476Joint estimation of relaxation and diffusion tissue parameters for prostate cancer with relaxation-VERDICT MRI.Sci Rep2023
36511804Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial.Radiology2023
34799996Effects of photobiomodulation therapy on regulation of myogenic regulatory factor mRNA expression in vivo: A systematic review.J Biophotonics2022
35885536Differentiating False Positive Lesions from Clinically Significant Cancer and Normal Prostate Tissue Using VERDICT MRI and Other Diffusion Models.Diagnostics (Basel)2022
35884558Comparison of Multiparametric Magnetic Resonance Imaging with Prostate-Specific Membrane Antigen Positron-Emission Tomography Imaging in Primary Prostate Cancer Diagnosis: A Systematic Review and Meta-Analysis.Cancers (Basel)2022
35916679Avoiding Unnecessary Biopsy after Multiparametric Prostate MRI with VERDICT Analysis: The INNOVATE Study.Radiology2022
34987040Relationship of prostate cancer topography and tumour conspicuity on multiparametric magnetic resonance imaging: a protocol for a systematic review and meta-analysis.BMJ Open2022
33185024Conspicuity of cribriform prostate cancer on multiparametric magnetic resonance imaging: the jury is still out.BJU Int2021
33823175Patient Perspectives and Understanding of MRI-directed Prostate Cancer Diagnosis.Urology2021
33924255Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial.Cancers (Basel)2021
34893484Prostate-specific membrane antigen positron emission tomography compared to multiparametric MRI for prostate cancer diagnosis: a protocol for a systematic review and meta-analysis.BMJ Open2021
34586984Micro-ultrasound vs. MRI for prostate cancer diagnosis: Considerations to address (Re: Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer, CUAJ, Jan 2021).Can Urol Assoc J2021
33958731Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models.Prostate Cancer Prostatic Dis2021
34059394Mapping Contemporary Biopsy Zones to Traditional Prostatic Anatomy: The Key to Understanding Relationships Between Prostate Cancer Topography, Magnetic Resonance Imaging Conspicuity, and Clinical Risk.Eur Urol2021
33980983The oncological relevance of fragile sites in cancer.Commun Biol2021
33952556Clinical outcomes associated with prostate cancer conspicuity on biparametric and multiparametric MRI: a protocol for a systematic review and meta-analysis of biochemical recurrence following radical prostatectomy.BMJ Open2021
34337543Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE Study.Eur Urol Open Sci2021
33375994A Modified Newcastle-Ottawa Scale for Assessment of Study Quality in Genetic Urological Research.Eur Urol2021
33278459Prostate Cancer Undetected by mpMRI: Tumor Conspicuity is Reliant Upon Optimal Scan Timing and Quality.Urology2021
33051065False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS.Eur Urol2021
31600865Genetic correlates of prostate cancer visibility (and invisibility) on multiparametric magnetic resonance imaging: it's time to take stock.BJU Int2020
31992607Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysis.BMJ Open2020
31941506Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report.BMC Cancer2020
33033409Author Correction: Genetic alterations in the 3q26.31-32 locus confer an aggressive prostate cancer phenotype.Commun Biol2020
33057024A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists.Sci Rep2020
33177621Author Correction: Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.Sci Rep2020
33093035Histopathological features of prostate cancer conspicuity on multiparametric MRI: protocol for a systematic review and meta-analysis.BMJ Open2020
33000006Genetic Landscape of Prostate Cancer Conspicuity on Multiparametric Magnetic Resonance Imaging: A Systematic Review and Bioinformatic Analysis.Eur Urol Open Sci2020
32796921Genetic alterations in the 3q26.31-32 locus confer an aggressive prostate cancer phenotype.Commun Biol2020
32676435Prostate cancer biology & genomics.Transl Androl Urol2020
32873828Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.Sci Rep2020
32698715Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?D. Deniffel, E. Salinas, M. Ientilucci, A. J. Evans, N. Fleshner, S. Ghai, R. Hamilton, A. Roberts, A. Toi, T. van der Kwast, A. Zlotta, A. Finelli, M. A. Haider and N. Perlis <i>J Urol</i> 2020; doi: 10.1097/JU.0000000000001157.J Urol2020
32920937Conspicuity of prostate cancer on multiparametric magnetic resonance imaging: A cross-disciplinary translational hypothesis.FASEB J2020
32581342Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer.Br J Cancer2020
32527691Re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol 2020;77:501-7.Eur Urol2020
32150588An optimised saliva collection method to produce high-yield, high-quality RNA for translational research.PLoS One2020
32360049Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study.Eur Urol2020
32296034PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.Signal Transduct Target Ther2020
32231090Exploring Patient Views and Acceptance of Multiparametric Magnetic Resonance Imaging for the Investigation of Suspected Prostate Cancer (the PACT Study): A Mixed-Methods Study Protocol.Methods Protoc2020
32319152Prostate cancer visibility on multiparametric magnetic resonance imaging: high Gleason grade and increased tumour volume are not the only important histopathological features.BJU Int2020
32370911What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort.Eur Urol2020
30958920Stroma in normal and cancer wound healing.FEBS J2019
31657791Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking.J Vis Exp2019
31450747The Oncogene Metadherin Interacts with the Known Splicing Proteins YTHDC1, Sam68 and T-STAR and Plays a Novel Role in Alternative mRNA Splicing.Cancers (Basel)2019
  • 1 - 50 of 95

Recommended Authors

The Prostate Cancer Clinical Trials Consortium
Career Start Year 2014
Number of shared co-authors 3
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 14
GenomeDx Biosciences Inc.
Career Start Year 2010
Number of shared co-authors 10
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 6
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 7
University of British Columbia
Career Start Year 2008
Number of shared co-authors 5
Institute for Pathology, University Hospital Schleswig-Holstein
Career Start Year 2007
Number of shared co-authors 1
Johns Hopkins University School of Medicine
Career Start Year 2006
Number of shared co-authors 9
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 6
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 10
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 19
University of British Columbia
Career Start Year 2004
Number of shared co-authors 3
Northwestern University
Career Start Year 2003
Number of shared co-authors 11
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 6
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 2003
Number of shared co-authors 13
University of Calgary Cumming School of Medicine, Rockyview General Hospital
Career Start Year 2002
Number of shared co-authors 10
University of British Columbia
Career Start Year 2002
Number of shared co-authors 16
Fred Hutchinson Cancer Center
Career Start Year 2001
Number of shared co-authors 9
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 7
Erasmus MC Cancer Institute, University Medical Center
Career Start Year 1998
Number of shared co-authors 13
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 1
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1997
Number of shared co-authors 25
David Geffen School of Medicine at university of california los angeles
Career Start Year 1993
Number of shared co-authors 12
Fred Hutchinson Cancer Center
Career Start Year 1993
Number of shared co-authors 20
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 9
University of Colorado School of Medicine
Career Start Year 1991
Number of shared co-authors 4
University of Bern
Career Start Year 1990
Number of shared co-authors 25
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1989
Number of shared co-authors 25
Skane University Hospital, Lund University
Career Start Year 1987
Number of shared co-authors 26
Institut du cancer de Montreal
Career Start Year 1985
Number of shared co-authors 13

Collaborators

University of Oxford, John Radcliffe Hospital
Co-authored papers 31
Cambridge University Hospitals National Health Service Foundation Trust
Co-authored papers 22
University College London
Co-authored papers 15
University of Cambridge
Co-authored papers 14
University of St Andrews
Co-authored papers 14
University College London
Co-authored papers 13
Norwich Medical School, University of East Anglia
Co-authored papers 13
Queen's University Belfast
Co-authored papers 11
The Institute of Cancer Research
Co-authored papers 11
University of Washington, USA Institute for Stem Cell and Regenerative Medicine
Co-authored papers 10
University Hospital Southampton NHS Foundation Trust
Co-authored papers 8
The Institute of Cancer Research
Co-authored papers 7
Cambridge University Hospitals NHS Foundation Trust
Co-authored papers 7
Norwich Medical School, University of East Anglia
Co-authored papers 7
University of Oxford
Co-authored papers 7
Memorial Sloan Kettering Cancer Center
Co-authored papers 7
The Institute of Cancer Research
Co-authored papers 7
Mayo Clinic
Co-authored papers 7
Wellcome Sanger Institute
Co-authored papers 7
Moores Cancer Center, university of california san diego
Co-authored papers 6
Manchester Cancer Research Centre, University of Manchester
Co-authored papers 6
University of Cambridge
Co-authored papers 6
Wellcome Sanger Institute
Co-authored papers 6
The Francis Crick Institute
Co-authored papers 6
Institute of Cancer Research
Co-authored papers 6
Memorial Sloan Kettering Cancer Center
Co-authored papers 6
University College London
Co-authored papers 5
Wellcome Sanger Institute
Co-authored papers 5
The Institute of Cancer Research
Co-authored papers 5
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Co-authored papers 5